Anokion raises $40M series B, grabs back programs from spinout

Alongside raising $40 million in a series B round, autoimmune company Anokion said Wednesday it will acquire Kanyos Bio, a company it spun out and partnered with Astellas in 2015.

Versant Ventures, Novartis Venture Fund, Novo Ventures, select Swiss-based private investors and Celgene Corp. (NASDAQ:CELG) participated in the series B round...